Vera Therapeutics is a late-stage biotechnology company developing atacicept, a native human TACI-Fc fusion protein that binds both B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) cytokines to treat serious autoimmune and immunological diseases. The company's lead candidate is in pivotal Phase 3 development for immunoglobulin A nephropathy and other autoimmune kidney diseases, with a pipeline that includes Phase 2 trials in expanded kidney disorders and acquired programs targeting BK virus reactivation in transplant recipients and next-generation dual BAFF/APRIL inhibitors. Vera plans to generate revenue through product sales of atacicept in the United States and key markets, supplemented by upfront payments, milestone payments, and royalties from exclusive license agreements with academic institutions and established pharmaceutical companies for its pipeline programs.